Effect of Vasa-Ghana And Kutaki-Ghana In The Management Of Heavy Menstrual Bleeding

A Comaparative Clinical Study Of Vasa-Ghan And Kutaki-Ghan In The Management Of Asrigdar W.S.R To Dysfunctional Uterine Bleeding - W.S.R- With Special Reference

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/03/012291

Enrollment

Registered

2018-03-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- 1.Participants complaining of Heavy menstrual bleeding (amount more than 80ml) Prolonged menstrual bleeding (With the duration of bleeding 7 days) ï??Inter menstrual bleeding

Interventions

Intervention1: Vasa-Ghana: 500mg twice a day with Munakka and Misri as Sahapana and water as Anupana for 60 days. Control Intervention1: Kutaki-Ghana Vati: 500mg twice a day with Munakka and Misri as

Eligibility

Inclusion criteria

Inclusion criteria: 1. Heavy menstrual bleeding (amount >80ml) 2. Prolonged menstrual bleeding (With the duration of bleeding >7 days) 3. Inter menstrual bleeding

Exclusion criteria

Exclusion criteria: 1. Participants having bleeding due to abortion. 2. Participants having coagulation disorders. 3. Participants having bleeding after menopause. 4. Any type of malignancy. 5. Pregnant women. 6. Participants having STIs. 7. Participants having systemic diseases like uncontrolled hypertension, chronic renal disease, chronic liver disease, insulin dependent diabetes mellitus, vascular diseases, etc. 8. Uterine and pelvic pathology like- Polyps, Endometrial TB, Fibroid, Adenomyosis, PID, etc. 9. Participants using IUCD.

Design outcomes

Primary

Measure	Time frame
To manage dysfunctional uterine bleeding.Timepoint: 60 days	—

Secondary

Measure	Time frame
Improve quality of lifeTimepoint: 2 months	—

Countries

India

Contacts

Public ContactDr Rachana Poudel

National Institute of Ayurveda

sushila.sharma.s@gmail.com9660843984

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026